What is Xarelto
RivaroxabanThe Generic name of this drug
Treatment SummaryRivaroxaban is a blood-thinning medication. It is the first of its kind that can be taken orally and works by stopping the body's natural formation of blood clots. Unlike other anticoagulants, Rivaroxaban does not require regular tests to monitor its effectiveness. However, there is no antidote available if a person experiences excessive bleeding. The 10 mg tablet can be taken without food, while the 15 mg and 20 mg tablets should be taken with food. Rivaroxaban was approved by the FDA in 2011.
Xareltois the brand name
Xarelto Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Xarelto
Rivaroxaban
2011
15
Approved as Treatment by the FDA
Rivaroxaban, otherwise called Xarelto, is approved by the FDA for 15 uses like Stroke and Disease .Stroke
Used to treat Cerebrovascular Accident in combination with Acetylsalicylic acid
Disease
Peripheral Arterial Disease
Used to treat Peripheral Arterial Disease (PAD) in combination with Acetylsalicylic acid
Chronic Coronary Artery Disease
Used to treat Chronic Coronary Artery Disease in combination with Acetylsalicylic acid
prophylaxis of systemic embolism
Systemic Embolism
Atrial Fibrillation
Cardiovascular Mortality
Used to treat Cardiovascular Mortality in combination with Acetylsalicylic acid
Deep Vein Thrombosis
Total Knee Arthroplasty
Deep Vein Thrombosis
Cerebrovascular accident prophylaxis
Pulmonary Embolism
Arthroplasty
Heart Attack
Used to treat Myocardial Infarction in combination with Acetylsalicylic acid
Effectiveness
How Xarelto Affects PatientsRivaroxaban is a medication that stops blood from clotting. It works by blocking a protein (called Factor Xa) that helps start the process of forming a blood clot. Rivaroxaban is different from other anticoagulants because it is taken orally, not injected, and it does not need another protein (called antithrombin III) to work. Testing the levels of rivaroxaban in the blood is not recommended as it does not give an accurate measure of how well the drug is working.
How Xarelto works in the bodyRivaroxaban stops the formation of blood clots by blocking a protein called factor Xa from activating. Factor Xa is needed to turn prothrombin into thrombin, which helps form a loose meshwork in the clotting process. Rivaroxaban prevents this process from happening, making it difficult for a clot to form. The effects of rivaroxaban are irreversible.
When to interrupt dosage
Condition
Dosage
Administration
Heart Attack
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Fontan Procedure
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Arthroplasty
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Deep Vein Thrombosis (DVT)
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Systemic Embolism
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Total Knee Arthroplasty
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Congenital Heart Defect
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Pulmonary Embolism
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Recurrent Venous Thromboembolism
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Stroke
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Atrial Fibrillation
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Cerebrovascular accident prophylaxis
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Cardiovascular Mortality
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Disease
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Deep Vein Thrombosis
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Peripheral Arterial Disease
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Deep Vein Thrombosis
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Chronic Coronary Artery Disease
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Deep Vein Thrombosis
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Thrombosis
2.5 mg, , 15.0 mg, 20.0 mg, 5250.0 mg, 2625.0 mg, 10.0 mg, 1.0 mg/mL, 103.4 mg, 51.7 mg, 155.0 mg
Kit; Tablet, film coated, Oral, Granule, for suspension - Oral, Granule, Tablet - Oral, Granule, for suspension, , Granule - Oral, Tablet, Tablet, film coated, Kit; Tablet - Oral, Tablet, film coated - Oral, Kit; Tablet, film coated - Oral, Kit; Tablet
Warnings
Xarelto ContraindicationsCondition
Risk Level
Notes
Hemorrhage
Do Not Combine
Common Xarelto Drug Interactions
Drug Name
Risk Level
Description
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Rivaroxaban.
Andexanet alfa
Major
The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Rivaroxaban.
Anti-inhibitor coagulant complex
Major
The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Rivaroxaban.
Antihemophilic factor (recombinant), PEGylated
Major
The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Rivaroxaban.
Antihemophilic factor human
Major
The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Rivaroxaban.
Xarelto Toxicity & Overdose RiskTaking too much of this drug can cause excessive bleeding. Treatment may include activated charcoal and other measures to help stop the bleeding. If the bleeding does not stop, a doctor may give procoagulants, such as activated prothrombin complex concentrate, prothrombin complex concentrate, or recombinant factor VIIa. People who take this drug may also have a higher chance of post-procedure bleeding compared to those taking enoxaparin.
Xarelto Novel Uses: Which Conditions Have a Clinical Trial Featuring Xarelto?
206 active trials are presently being conducted to assess the effectiveness of Xarelto in Total Knee Replacement, Recurrent Venous Thromboembolism and Deep Vein Thrombosis interventions.Condition
Clinical Trials
Trial Phases
Total Knee Arthroplasty
12 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 4
Cardiovascular Mortality
0 Actively Recruiting
Cerebrovascular accident prophylaxis
0 Actively Recruiting
Disease
0 Actively Recruiting
Chronic Coronary Artery Disease
0 Actively Recruiting
prophylaxis of systemic embolism
0 Actively Recruiting
Deep Vein Thrombosis
0 Actively Recruiting
Fontan Procedure
0 Actively Recruiting
Atrial Fibrillation
2 Actively Recruiting
Not Applicable
Thrombosis
0 Actively Recruiting
Deep Vein Thrombosis (DVT)
27 Actively Recruiting
Phase 4, Phase 3, Not Applicable, Phase 1, Phase 2, Early Phase 1
Systemic Embolism
1 Actively Recruiting
Not Applicable
Deep Vein Thrombosis
15 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 4, Phase 2
Congenital Heart Defect
38 Actively Recruiting
Phase 2, Not Applicable, Phase 4, Phase 3, Phase 1
Recurrent Venous Thromboembolism
0 Actively Recruiting
Deep Vein Thrombosis
0 Actively Recruiting
Arthroplasty
8 Actively Recruiting
Not Applicable, Phase 4
Stroke
14 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Pulmonary Embolism
30 Actively Recruiting
Not Applicable, Early Phase 1, Phase 4, Phase 3, Phase 1, Phase 2
Heart Attack
66 Actively Recruiting
Phase 4, Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Xarelto Reviews: What are patients saying about Xarelto?
5Patient Review
9/6/2022 I haven't had any of the side effects mentioned by other people on this site. I would rather take this medication than risk a blood clot resulting in stroke or death.
5Patient Review
9/13/2019 I had a pulmonary embolism and started this treatment six years ago. I have not experienced any negative side effects from it.
5Patient Review
5/14/2022 I've been using this medication for three months now and I couldn't be happier. No side effects whatsoever.
5Patient Review
11/2/2020 There are no adverse effects to taking this medication. I would recommend doing so at bedtime. Whenever I have cut myself while on this medication, the bleeding has been minimal.
4.3Patient Review
9/3/2021 I've been on Xarelto for half a year now, and it's kept the blood clot in my heart at bay. I haven't had any serious side effects that I know of, though there is an unusual rash on my forearm that won't go away. My doctor suggested a "Watchman" procedure if I want to stop taking this medication, but I'm not sure if that's the best idea.
4Patient Review
9/18/2019 I've started having rashes and swellings on my limbs since I began taking this medication. My doctors thought it might be gout or arthritis, but since I never had any problems like this before starting to take Xarelto, I'm more inclined to believe that it's a side effect of the drug. My right leg has been swollen for ten days now.
3.7Patient Review
6/10/20193Patient Review
3/24/2022 I have been experiencing a lot of pain in my legs and feet. Recently, it has started to affect my arms and neck as well. I've had check-ups for everything possible, but sadly I think it might be the Xeralto. I won't touch it ever again; the pain and weakness is unreal. I hope it eventually stops...
3Patient Review
3/15/2020 Xarelto has been nothing but trouble for me. It's given me joint pain and made it difficult to move around.
2.3Patient Review
11/10/2020 My husband died from a brain hemorrhage after taking this drug. Please, do not use it.
2Patient Review
11/16/2021 I had to stop taking this medication before finishing the course due to strong side effects. Even now, six months later, I'm still experiencing nausea, loss of appetite, and a burning sensation in my stomach.
2Patient Review
11/21/2019 I was experiencing pain and weakness in both of my legs when I tried this treatment.
1Patient Review
6/9/2022 I tried this medication for atrial fibrillation. The first pill resulted in the next day waking up to a total loss of use of my left leg. The second pill then caused a total loss of use of my right leg. That's all I took before quitting; and fortunately, after discontinuing usage my leg function returned. However, subsequent to this experience, my physical therapy was extended for 3 months - so it's clear that insurance companies are aware of these types of side effects from the drug.
Patient Q&A Section about xarelto
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are the serious side effects of Xarelto?
"The following are symptoms of cervical cancer: back pain, bloody stools, bowel or bladder dysfunction, burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings, coughing up blood, difficulty with breathing or swallowing, headache, increased menstrual flow or vaginal bleeding."
Answered by AI
What is better eliquis or Xarelto?
"Medication A (apixaban/Eliquis) is better than medication B (rivaroxaban/Xarelto) for stroke prevention in patients with atrial fibrillation, according to a study published in JAMA. Medication A was associated with reduced rates of severe bleeding complications and strokes."
Answered by AI
Why was Xarelto taken off the market?
"Xarelto also has a number of additional side effects, including abdominal bleeding, brain hemorrhage, abnormal liver function and reduced platelet levels. Janssen Pharmaceuticals issued a voluntary recall of 13,500 bottles of Xarelto last October due to a microbial contamination discovered in a sample."
Answered by AI
What is the most common side effect of Xarelto?
"Common side effects of Xarelto include bleeding. Xarelto is an anticoagulant drug that makes it harder for your body to form blood clots, so an increased risk for bleeding is to be expected."
Answered by AI
Why is Xarelto taken at night?
"XARELTO should be taken orally once daily with the evening meal."
Answered by AI
What is Xarelto used for?
"This can lead to blood clots, which can travel to the brain, causing a stroke, or to other parts of the body
XARELTO is a prescription medication used to reduce the risk of stroke and blood clots in adults who have a medical condition called atrial fibrillation."
Answered by AI